All In Biotech

Drug Trial Radar · NCT06537999

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Sep 17, 2024

Primary completion

Dec 2026

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Dianthus TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).

Conditions

  • Multifocal Motor Neuropathy

Interventions

  • ClaseprubartDrug

    * Day 1: IV loading dose * Week 1 to Week 15: Claseprubart administered SC every 2 weeks

  • PlaceboDrug

    * Day 1: IV infusion of placebo * Week 1 to Week 15: placebo administered SC every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)Time frame: Baseline to Week 17

Locations

41 sites in 15 countries. Site status is shown where the registry gives one.

  • Clinical Study Site

    Scottsdale, Arizona

  • Clinical Study Site

    Los Angeles, California

  • Clinical Study Site

    Bradenton, Florida

  • Clinical Study Site

    Tampa, Florida

  • Clinical Study Site

    Honolulu, Hawaii

  • Clinical Study Site

    Kansas City, Kansas

  • Clinical Study Site

    Cincinnati, Ohio

  • Clinical Study Site

    Columbus, Ohio

  • Clinical Study Site

    Houston, Texas

  • Cinical Study Site

    Toronto, Canada

  • Cinical Study Site

    Beijing, China

  • Clinical Study Site

    Beijing, China

  • Cinical Study Site

    Shanghai, China

  • Clinical Study Site

    Aarhus, Denmark

  • Clinical Study Site

    Copenhagen, Denmark

  • Clinical Study Site

    Marseille, France

  • Clinical Study Site

    Paris, France

  • Clinical Study Site

    Rome, Italy

  • Clinical Study Site

    Kota Kinabalu, Malaysia

  • Cinical Study Site

    Kuala Lumpur, Malaysia

  • Cinical Study Site

    Kuala Lumpur, Malaysia

  • Cinical Study Site

    Permatang Pauh, Malaysia

  • Cinical Study Site

    Sarawak, Malaysia

  • Clinical Study Site

    Amsterdam, Netherlands

  • Clinical Study Site

    Utrecht, Netherlands

  • Clinical Study Site

    Skopje, North Macedonia

  • Clinical Study Site

    Bydgoszcz, Poland

  • Clinical Study Site

    Katowice, Poland

  • Clinical Study Site

    Krakow, Poland

  • Clinical Study Site

    Krakow, Poland

  • Clinical Study Site

    Belgrade, Serbia

  • Cinical Study Site

    Daegu, South Korea

  • Cinical Study Site #2

    Seoul, South Korea

  • Clinical Study Site

    Seoul, South Korea

  • Cinical Study Site

    Alicante, Spain

  • Clinical Study Site

    Barcelona, Spain

  • Cinical Study Site

    Barcelona, Spain

  • Cinical Study Site

    Istanbul, Turkey (Türkiye)

  • Clinical Study Site

    London, England, United Kingdom

  • Clinical Study Site

    Oxford, England, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.